Profile: Novo Nordisk Canada, Inc. is a healthcare company, which provides diabetes product. Our product line includes Activelle®, Activelle® LD, Levemir®, NiaStase®, NovoMix® 30, NovoRapid® and Novolin-Penr Junior. Our Activelle® is ideal for the treatment of moderate to severe vasomotor symptoms occurring in naturally or surgically induced estrogen deficiency states and for the treatment of vulvar or vaginal atrophy associated with menopause. It contains 1 mg of estradiol and 0.5 mg norethindrone acetate. Our Levemir® is a sterile solution of insulin detemir for use as an injection. Insulin detemir is a long-acting basal insulin analogue. It is ideal for the treatment of adult patients with type 1 or type 2 diabetes mellitus who require a long acting insulin for the control of hyperglycemia, for the treatment of pediatric patients with type 1 diabetes mellitus ,and for the treatment of type 2 diabetes mellitus in combination with oral anti-diabetic agents in adult patients who do not have adequate metabolic control.

The company has revenues of < USD 1 Million, has ~100 employees. NYSE:NVO (SEC Filings)